We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Exenatide therapy in insulin-treated type 2 diabetes and obesity.
- Authors
Nayak, U. A.; Govindan, J.; Baskar, V.; Kalupahana, D.; Singh, B. M.
- Abstract
Background: Exenatide, a GLP-1 analogue, is used in combination with oral anti-diabetic agents in type 2 diabetes and obesity, and promotes weight loss. Exenatide use in combination with insulin in insulin-treated type 2 diabetes and obesity is unlicensed in the UK and outcomes are unclear. Aims: To assess the effectiveness of exenatide in insulin-treated type 2 diabetes with obesity. Design and Methods: This prospective study included 174 consecutive patients with insulintreated type 2 diabetes and obesity initiated on exenatide in our out-patient, between October 2007 and November 2008. Weight, BMI, HbA1c, serum fructosamine, total cholesterol, HDLcholesterol and insulin doses were recorded at baseline, 3, 6 and 12 months. Side effect profiles were recorded. Results: Fourteen patients discontinued exenatide before 3 months of initiation, because of side effects, and were excluded. Data were analysed on remaining 160 people all of whom completed 6 months and 57 completed 12 months treatment. Mean weight loss was 10.7±5.7 kg and 12.8±7.5 kg (P<0.001) at 6 and 12 months. Insulin doses dropped significantly (mean 144±90 U/day at baseline to 51±55 U/day and 55±53 U/day at 6 and 12 months). At 3 months, 25% came off insulin. There was little change in HbA1c. Conclusions: Exenatide therapy in insulin-treated type 2 diabetes and obesity was associated with very significant reductions in weight and insulin doses. Exenatide should be considered in people with type 2 diabetes on insulin and have obesity, weight gain and poor glycaemic control.
- Subjects
UNITED Kingdom; INSULIN research; TYPE 2 diabetes; OBESITY; WEIGHT loss
- Publication
QJM: An International Journal of Medicine, 2010, Vol 103, Issue 9, p687
- ISSN
1460-2725
- Publication type
Article
- DOI
10.1093/qjmed/hcq112